Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
On the Downside Radar: financing pressure. About 11.6 months of cash at its recent burn rate (Sep 30, 2026 balance sheet), an at-the-market (ATM) program filed Apr 3, 2026, and no offering in the last 90 days. Of biotech stocks in this setup with 6 to 12 months of cash, 35% sold new shares within three months and 67% were lower 60 trading days later (median -12%). How we know
$60.3MCash on Hand
11.6mo Cash Runway
Follow AARD by emailGet an email when AARD reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about AARD, unsubscribe in one click. Privacy
📣 What AARD Says Is Next
in 2027 · ARD-101: “FDA lifted full clinical hold on ARD-101; Company plans to request FDA meeting to align on new Phase 3 trial design and expects to resume PWS clinical activities in 2027”
Company press release, Oct 23, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 13, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Nov 13, 2026 ·
Earnings Reported Q3 2026 results: $60.3 million in cash, cash equivalents and short-term investments as of September 30, 2026, sufficient to fund operations through 2027. Net loss was $19.2 million. FDA lifted the ARD-101 clinical hold in October, with an FDA meeting set for Q1 2027. Form 8-K · SEC filing · Press release
Oct 23, 2026 ·
Clinical trial Reported exploratory efficacy data from the terminated Phase 3 HERO trial (67 of 90 planned participants randomized) and open-label extension. OLE participants switching from placebo to ARD-101 saw an average 6-point HQ-CT reduction. FDA lifted the clinical hold; company plans an FDA meeting on a new Phase 3 design. Form 8-K · SEC filing · Press release
Oct 22, 2026 ·
Regulatory FDA lifted the clinical hold on the ARD-101 IND for hyperphagia in Prader-Willi Syndrome, so clinical development may resume. Aardvark also plans a Friday webcast on October 23, 2026 at 8:00 a.m. ET to review data from the terminated Phase 3 HERO and OLE trials. Form 8-K · SEC filing · Press release
Oct 8, 2026 ·
Leadership Aardvark Therapeutics appointed David Zhang, Ph.D., MBA, as a Class II independent director effective October 7, 2026. He receives $40,000 annual cash compensation and an option grant worth $500,000 vesting monthly over three years. He is Chief Strategy Officer of Abivax S.A. Form 8-K · SEC filing · Press release
Aug 17, 2026 ·
Shareholder vote Stockholders elected Victor Tong, Jr. and Jeffrey Chi, Ph.D. as Class I directors, ratified BDO USA, P.C. as auditor for 2026, and approved repricing certain outstanding stock options held by Eligible Participants. Quorum was 54.79%. Form 8-K · SEC filing
Aug 11, 2026 ·
Earnings Reported Q2 2026 results: net loss of $14.4 million, cash of $73.9 million as of June 30, 2026, funding operations into late 2027. Terminated the HERO and OLE trials for ARD-101 in June 2026, and the FDA placed a full clinical hold on the IND in May 2026. Form 8-K · SEC filing · Press release
Aug 11, 2026 ·
Quarterly report for the period ended Jun 30, 2026 Form 10-Q · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Jan 2025 · Phase 2 · Results Expected · A Study to Evaluate ARD-501 in Patients With Autism Spectrum Disorder Registry primary completion date, not a results date
Sep 2024 · Phase 2 · Results Expected · A Study of Oral ARD-101 in Patients With Prader-Willi Syndrome Registry primary completion date, not a results date
Feb 2023 · Phase 2 · Results Expected · Study to Evaluate ARD-101 in Adults Receiving Bariatric Surgery Registry primary completion date, not a results date
Nov 2022 · Phase 2 · Results Expected · Study to Evaluate ARD-101 in Adults With Obesity Registry primary completion date, not a results date
Aug 2009 · N/A · Results Expected · Home Usability of a Nasal Lavage System in Children Registry primary completion date, not a results date
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
AARD holds $60.3M in cash and short-term investments (as of Sep 30, 2026) and burns about $15.6M/quarter from operations,
an estimated runway of 11.6 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:50 · Elevated
Cash runway 12 months +30
ATM program on file since Apr 2026 +15
Shelf registration (S-3, Mar 2026) +10
Company says cash lasts through 2027 -5Based upon our current operating plans, we believe that our existing cash, cash equivalents and short-term investments will be sufficient to fund our projected operations through 2027.10-Q, Nov 2026
Share count 21,891,271 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full AARD picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for AARD and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.